Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 5/20 | 0.48 |
| ▸ | ESR2 | Q92731 | 5/20 | 0.48 |
| ▸ | ABHD6 | Q9BV23 | 7/20 | 0.37 |
| ▸ | MGLL | Q99685 | 4/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.34 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.34 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.34 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.34 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23684362 | 0.77 | HRH3 (0.41) | CYP4F2CYP4A11 | |
| SCHEMBL8176141 | 0.77 | ESR1 (0.61) | ESR1ESR2ABHD6PKMPDE4B | |
| SCHEMBL22070894 | 0.74 | CYP4F2 (0.58) | ESR1ESR2CYP4F2CYP4A11 | |
| SCHEMBL3893409 | 0.71 | ESR1 (0.75) | ESR1ESR2ABHD6MGLLNPC1 | |
| SCHEMBL23684059 | 0.69 | HRH3 (0.43) | ESR1ESR2ABHD6S1PR1 | |
| SCHEMBL23684648 | 0.68 | ESR2 (0.57) | ESR1ESR2ABHD6 | |
| SCHEMBL3895230 | 0.67 | ESR1 (1.00) | ESR1ESR2ABHD6NPC1RAB9A | |
| SCHEMBL22070627 | 0.66 | CYP4F2 (0.64) | CYP4F2CYP4A11 | |
| SCHEMBL8176145 | 0.65 | ESR2 (1.00) | ESR1ESR2ABHD6PKM | |
| SCHEMBL23684595 | 0.65 | ALDH1A1 (0.38) | ESR1POLBCYP4F2CYP4A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11986471-B2 | Compounds and methods of use | TANGO THERAPEUTICS, INC. (US) | 2024-05-21 | — | — | US | disclosed |
| US-20230060499-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2023-03-02 | — | — | US | disclosed |
| US-20230060499-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2023-03-02 | — | — | US | disclosed |
| US-11077101-B1 | Compounds and methods of use | TANGO THERAPEUTICS, INC. (US) | 2021-08-03 | — | — | US | disclosed |
| US-11077101-B1 | Compounds and methods of use | TANGO THERAPEUTICS, INC. (US) | 2021-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11986471-B2 | Compounds and methods of use | XDH, F12, LPXN | ESR1 791/4885ESR2 1084/4885ABHD6 3657/4885 |
| US-11077101-B1 | Compounds and methods of use | XDH, F12, LPXN | ESR1 791/4885ESR2 1084/4885ABHD6 3657/4885 |
| US-20230060499-A1 | COMPOUNDS AND METHODS OF USE | XDH, F12, LPXN | ESR1 791/4885ESR2 1084/4885ABHD6 3657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.